Proximal femur fractures pose a real challenge in the medical field, especially among older adults, as these injuries often lead to significant complications and even higher mortality rates [1]. It's essential to manage pain effectively in these patients to facilitate early movement, lower the chances of postoperative issues, and ultimately improve their overall health outcomes [2]. Recently, regional anaesthesia techniques have become more popular because they provide effective pain relief while reducing the need for systemic opioids. One such technique, the fascia iliaca block (FICB), has proven to be particularly useful for alleviating pain during lower limb surgeries, including repairs for proximal femur fractures [3].

Ropivacaine, a long-acting amide-type local anaesthetic, is commonly used in these regional blocks due to its favorable safety profile, which includes lower risks of cardiotoxicity and neurotoxicity, along with its ability to deliver extended sensory relief with minimal impact on motor function. This makes it an excellent choice for elderly and high-risk patients undergoing lower limb surgeries [5][6]. However, there's still a need to boost the effectiveness and duration of pain relief that ropivacaine can provide on its own. As a result, researchers have been looking into adding pharmacological adjuvants to local anaesthetics as a way to enhance both the quality and duration of these regional blocks [4].

Magnesium sulphate has been making waves as a promising adjuvant, thanks to its unique way of working. It mainly acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor and also blocks calcium channels. These actions are crucial for modulating pain transmission. By targeting the posterior horn of the spinal cord, it effectively dampens the excitatory effects of amino acids like glutamate and aspartate, which helps enhance pain relief. What’s more, magnesium is seen as a safer NMDA antagonist because it doesn’t easily cross the blood-brain barrier, which lowers the chances of central nervous system side effects.

The role of magnesium sulphate as an adjuvant to local anaesthetics in various regional anaesthesia techniques has been explored before, often showing positive outcomes like longer-lasting pain relief, deeper sensory blocks, and quicker onset of action. However, there’s still not much evidence about how effective it is when combined with ropivacaine, especially in ultrasound-guided fascia iliaca compartment blocks for surgeries involving proximal femur fractures. This specific approach focuses on the fascia iliaca compartment, a space nestled between the fascia iliaca and the iliopsoas muscle. When local anaesthetic is injected here, it blocks the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve—key players in the sensory innervation of the hip and front of the thigh. Using ultrasound guidance makes this technique more precise, which helps reduce complications and boosts the overall success rate of the block.

This randomized controlled trial was set up to take a closer look at how effective and safe ropivacaine is when used alone compared to when it's combined with magnesium sulphate in ultrasound-guided fascia iliaca blocks for patients having surgery for proximal femur fractures. By focusing on this particular combination of drugs in a well-defined clinical environment, the study aims to fill a gap in existing research and provide solid evidence to guide best practices. The trial is all about figuring out if adding magnesium sulphate to ropivacaine can help lower the need for opioids after surgery and extend the duration of the sensory block, all while keeping patient safety intact. In doing so, it adds to the growing evidence that supports using multimodal analgesia techniques to enhance pain management and recovery after surgery, especially for patients who are more vulnerable.

Study Design and Setting 

This research was a prospective randomized controlled trial that took place at the Department of Anaesthesiology, Kalinga Institute of Medical Sciences, Pradyumna Bal Memorial Hospital (PBMH), KIIT University, located in Bhubaneswar, Odisha. The study ran from March 2023 to November 2024 and was officially registered with the Clinical Trial Registry of India (CTRI) under the number CTRI/2023/05/052200.

Ethical Considerations 

Before starting, the study protocol was approved by the Institutional Ethics Committee of KIIT University (Approval Number: KIIT/KIMS/IEC/1218/2023). We made sure to follow the ethical guidelines set out in the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice (ICH-GCP) standards. All participants provided written informed consent, and they received a Participant Information Sheet (PIS) in their local language. Consent was confirmed either through a signature or a thumb impression. Patient data were gathered from the hospital record system after obtaining the necessary permissions from the relevant authorities.

Study Population 

The study focused on adult patients aged 18 and older who were set to undergo surgery for proximal femur fractures. To be eligible, participants needed to be classified as American Society of Anesthesiologists (ASA) physical status I or II. Those with known allergies to the study medications, chronic pain conditions, a history of opioid or analgesic misuse, alcohol dependency, coagulopathy, local infections or sepsis, severe kidney failure, myasthenia gravis, pulmonary edema, or existing heart block were excluded from the study.

Sample Size Calculation 

Drawing from previous research, especially the work by Gupta M et al. [7], and using OpenEpi software with a 95% confidence interval and 80% power, we estimated that a minimum of 23 patients per group was necessary. To prepare for potential dropouts and ensure we had enough statistical power, we ultimately enrolled 50 patients, dividing them into two groups of 25.

Randomization and Blinding 

We conducted randomization using a computer-generated table. Participants were assigned to one of the two study groups through opaque sealed envelopes to keep the allocation process hidden. To minimize any bias from observers, the staff involved in preparing and administering the block were not part of the team assessing the outcomes.

Intervention Protocol

All patients underwent spinal anaesthesia while sitting, receiving 3 mL of 0.5% bupivacaine along with 5 mcg of dexmedetomidine. After the surgery wrapped up, patients were given an ultrasound-guided fascia iliaca block (FICB) based on their assigned group. This block was done using a 10 cm B Braun Stimuplex needle, guided by a high-frequency linear ultrasound probe (9–12 MHz).

In Group I, patients received 20 mL of 0.2% ropivacaine mixed with 150 mg of magnesium sulphate, while Group II got 20 mL of 0.2% ropivacaine by itself. The medication was carefully placed at the traditional anatomical site for the fascia iliaca compartment, ensuring it spread adequately under ultrasound guidance.

Postoperative Monitoring and Analgesia Assessment

Once the surgical procedure was completed and the block was administered, patients were moved to the Post-Anaesthesia Care Unit and then to the surgical ward. Pain levels were assessed using the Visual Analogue Scale (VAS), which ranges from 0 (no pain) to 10 (the worst pain imaginable). These evaluations took place every 2 hours for the first 24 hours after surgery. If patients reported significant pain, rescue analgesia in the form of intravenous tramadol 100 mg diluted in 100 mL of normal saline was provided, following the institutional protocol.

Outcome Measures

The main focus of our study was to determine how long the analgesia lasted, which we measured by looking at the time from when the block was administered (T0) until the first request for additional pain relief. We also looked at secondary outcomes, such as pain levels recorded on the VAS scale, along with any complications or side effects that occurred during the 24 hours following surgery.

Statistical Analysis

We organized the data from both groups using Microsoft Excel 365 and then analyzed it further with SPSS version 24. Continuous variables like age, weight, duration of analgesia, and VAS scores were reported as either mean ± standard deviation or median with interquartile range, depending on how the data was distributed. To compare continuous variables between the groups, we used the unpaired t-test for data that followed a normal distribution, and the Mann-Whitney U test for data that did not. For repeated measures within groups, we applied repeated measures ANOVA or the Friedman test, as appropriate. We compared categorical variables, such as gender distribution, the need for rescue analgesia, and the occurrence of complications, using the Chi-square test or Fisher's exact test. We considered a p-value of less than 0.05 to be statistically significant for all analyses.

Baseline Characteristics

Both groups showed similar baseline demographics and clinical parameters. There were no significant differences in age, gender distribution, weight, height, BMI, surgical duration, or preoperative vital signs (like SBP, DBP, HR). The types of procedures performed (such as hemiarthroplasty and nailing) were also quite similar, even though there were some minor numerical differences. This indicates that the randomization between Group I (Ropivacaine + MgSO₄) and Group II (Ropivacaine alone) was balanced.

Table 1: Baseline and Surgical Characteristics

Statistical tests: Unpaired t-test (age, weight, surgery duration, SBP); Fisher’s Exact Test (gender).

Postoperative Pain Outcomes

The progression of pain, measured using VAS scores, was almost the same for both groups. Scores stayed at 0 until the 4-hour mark, peaked between 12 and 14 hours (Group I: 2.4 ± 0.5; Group II: 2.28 ± 0.54), and then leveled out by 24 hours (both at 2.0 ± 0). There were no significant differences at any time point (all p>0.05), although Group II did show a slight trend towards higher pain levels at the 20-hour mark (p=0.0556). A repeated-measures ANOVA confirmed that there were significant changes over time in both groups (p<0.0001).

Table 2: VAS Scores Over Time

Rescue Analgesia Requirements

The use of rescue analgesia didn’t show any significant differences between the groups. However, Group II did need analgesia sooner in 24% of patients at the 20-hour mark, compared to just 8% in Group I (p=0.2467). Despite this, the average time to the first rescue was quite similar: Group I had 12.08 ± 4.49 hours, while Group II was at 14.08 ± 4.88 hours (p=0.1382). When it comes to total tramadol consumption, both groups were pretty much on par, with Group I using 136.0 ± 48.99 mg and Group II at 144.0 ± 50.66 mg (p=0.5730).

Table 3: Rescue Analgesia and Tramadol Use

Adding MgSO₄ to ropivacaine for spinal anesthesia didn't really show any meaningful benefits in terms of postoperative pain management, the need for rescue analgesia, or tramadol usage when compared to using ropivacaine on its own. The differences we saw in VAS scores, the timing of analgesia, and opioid consumption were both clinically and statistically insignificant.

The current study looked into how effective Ropivacaine is on its own compared to when it's mixed with Magnesium Sulfate (MgSO₄) during ultrasound-guided fascia iliaca compartment block (FICB) for pain relief after surgery on the proximal femur. The goal was to see if adding MgSO₄ could boost the pain-relieving effects of Ropivacaine, lessen the need for additional pain relief, and extend the duration of pain relief after surgery.

Magnesium Sulfate is recognized for its pain-relieving qualities, mainly by blocking N-methyl-D-aspartate (NMDA) receptors. By reducing central sensitization and controlling calcium flow at presynaptic terminals, MgSO₄ might enhance the effectiveness of local anesthetics. In theory, combining it with Ropivacaine could lead to lower pain levels and reduced opioid use after surgery. However, the results of this study didn’t show any significant advantages of MgSO₄ in the areas examined.

The demographic and baseline characteristics of both groups were well matched, with no notable differences in age, gender, body weight, or hemodynamic parameters. This indicates that randomization was effective and helped minimize any potential confounding factors. Additionally, intraoperative factors like the length of surgery and the level of sensory blockade achieved were similar across both groups, ensuring a consistent surgical and anesthetic experience for all participants.

After surgery, we looked at pain scores using the Visual Analog Scale (VAS), and both groups showed a similar trend over the first 24 hours. Pain levels hit their highest point around 12 to 14 hours after the operation and then started to taper off. Interestingly, Group II, which received Ropivacaine alone, had a slightly higher VAS score at the 20-hour mark, but this difference wasn’t statistically significant (p = 0.0556). This trend hints at a possible delayed analgesic effect from MgSO₄, although we can’t draw any firm conclusions about its clinical importance just yet.

We also took a close look at analgesic consumption as a key outcome. The time it took for patients to need their first rescue analgesia and the total amount of tramadol used were pretty much the same across both groups. This suggests that adding MgSO₄ didn’t really make a difference in how long effective pain relief lasted or in reducing the need for opioid-based rescue meds. Using tramadol as a standard rescue analgesic for both groups helped keep our measurements consistent [12].

These findings are in line with some earlier studies, like those by Safa B et al. [8] and Monzon DG et al. [9], which showed that Ropivacaine alone can provide effective postoperative pain relief without needing additional medications. On the flip side, other research, including work by Deshpande J et al. [11], Gupta M et al. [7], and Santoshilaxmi et al. [10], has shown mixed results regarding the benefits of MgSO₄ as an add-on, especially in different surgical settings, drug dosages, or patient demographics. For instance, while Deshpande et al. [11] found that Dexamethasone worked better than MgSO₄ for prolonging pain relief, they also observed that patients using MgSO₄ were able to move around more quickly, indicating it might have specific advantages depending on what the clinical goals are.

The differences in findings across various studies highlight just how complex analgesic outcomes can be, especially when you consider the role of the procedural context. Take, for example, the work by Gupta M and colleagues on labor analgesia, where they found that MgSO₄ significantly boosted pain relief. However, this might not apply directly to orthopedic surgeries, given the different pain pathways and physiological responses involved [13,14].

The rationale for using MgSO₄ as an adjuvant is still solid. It works both at the peripheral level and, to a lesser extent, centrally by blocking NMDA receptors and calcium channels. Yet, how well it translates into clinical practice seems to rely heavily on the specific situation. For instance, MgSO₄ has been shown to lower opioid use after surgery when given through the epidural route, but its effects with peripheral nerve blocks like FICB can be quite inconsistent [15].

This current study also faced some limitations that could have affected the results. With only 25 patients in each group, the study's ability to detect subtle but important differences might be limited. Additionally, the variety of surgical procedures performed could have led to differences in postoperative pain experiences, impacting the reliability of the outcomes. Plus, while motor block wasn't evaluated, the use of 0.2% Ropivacaine, which is known for causing minimal motor blockade, likely wouldn't lead to significant motor impairment.

To wrap things up, adding Magnesium Sulfate to Ropivacaine in FICB didn’t show any significant benefits in managing postoperative pain, extending the duration of pain relief, or reducing the need for opioids when compared to using Ropivacaine on its own. Although there was a slight trend suggesting that the MgSO₄ group might have lower late-phase pain relief needs, it’s hard to say how meaningful that really is. We definitely need more large-scale, well-controlled studies to dig deeper into how MgSO₄ could work as an add-on in regional anesthesia, especially looking at different dosing methods, types of surgeries, and outcome measures to really understand its potential benefits.

To wrap things up, this randomized controlled study looked into how effective Magnesium Sulfate is when used alongside Ropivacaine in ultrasound-guided fascia iliaca compartment blocks for surgeries on the proximal femur. The results showed no significant benefits regarding postoperative pain scores, how long the analgesia lasted, the time until the first rescue analgesia, or the total opioid use in the first 24 hours. While it was noted that combining Ropivacaine with Magnesium Sulfate was safe, it didn’t really provide any meaningful clinical advantages over using Ropivacaine by itself in this context. This suggests that Ropivacaine alone is still a solid option for managing pain after these procedures. However, the trends observed—despite not being statistically significant—do call for more research. Future studies with larger and more varied groups, along with longer follow-up times, are essential to gain a clearer understanding of how Magnesium Sulfate might work as an adjuvant and to improve pain management strategies.

1. Kaye AD, Baluch A, Scott JT. Pain Management in the Elderly Population: A Review. Ochsner J. 2010;10(3):179-187
2. Fallon F, Moorthy A, Skerritt C, Crowe GG, Buggy DJ. Latest Advances in Regional Anaesthesia. Medicina. 2024;60(5):735. doi: 10.3390/medicina60050735
3. Simpson D, Curran MP, Oldfield V, Keating GM. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65(18):2675-717. doi: 10.2165/00003495-200565180-00013. PMID: 16392884.
4. Godoy Monzon D, Iserson KV, Vazquez JA. Single fascia iliaca compartment block for post-hip fracture pain relief. J Emerg Med. 2007 Apr;32(3):257-62. doi: 10.1016/j.jemermed.2006.08.011. Epub 2007 Feb 8. PMID: 17394987.
5. Ahilasamy N, Kumar RD, Nayagam HA, Shanmuganandam O, Vaibhavi KR, Modak V. Ropivacaine: A Novel Local Anaesthetic Drug to Use in Otorhinolaryngology Practice. Indian J Otolaryngol Head Neck Surg. 2021;73:267- 70
6. Shambhavi T, Das S, Senapati LK, Padhi PP. Comparative evaluation of bupivacaine with magnesium sulphate and dexamethasone as adjuvants in ultrasound-guided transversus abdominis plane block for open unilateral inguinal hernia surgeries: A randomised controlled trial. Indian J Anaesth. 2023 Apr;67(4):370-375. doi: 10.4103/ija.ija_1091_21. Epub 2023 Apr 10. PMID: 37303878; PMCID: PMC10248895
7. Gupta M, Kumari I, Sharma S, Aggarwal A. Evaluation of the efficacy of MgSO4 as an adjunct to ropivacaine and fentanyl for labour analgesia. J Obstet Anaesth Crit Care 2020;10:10-5
8. Safa B, Trinh H, Lansdown A, McHardy PG, Gollish J, Kiss A, et al. Ultrasoundguided suprainguinal fascia iliaca compartment block and early postoperative analgesia after total hip arthroplasty: a randomised controlled trial. British Journal of Anaesthesia. 2024 May 18;133(1):146–51.
9. Monzon DG, Iserson KV, Vazquez JA. Single Fascia Iliaca Compartment Block for Post-Hip Fracture Pain Relief. The Journal of Emergency Medicine. 2007 Apr;32(3):257–62.
10. CD Santoshilaxmi, Kakhandki S. Comparison of efficacy of magnesium sulphate and dexamethasone as adjuvants to ropivacaine in ultrasound guided Suprainguinal Bibliography 119 fascia Iliaca block administered before regional Anaesthesia for patients undergoing proximal femur fracture surgeries. International Journal of Medical Anesthesiology. 2020 Jul 1;3(3):52–5.
11. Deshpande J, Kulkarni P, Nashine S. Efficacy of Magnesium vs Dexamethasone as an Adjuvant to Ropivacaine in Ultrasound Guided Femoral and Sciatic Nerve Block for Postoperative Analgesia: A Prospective, Double Blinded Randomized Controlled Study. Archives of Anesthesiology and Critical Care (Autumn 2023); 9(Supplement 2): 530-535.
12. Do SH. Magnesium: A versatile drug for anaesthesiologist. Korean J Anesthesiol. 2013;65:4- 8.
13. Telci L, Esen F, Akcora D, Erden T, Canbolat AT, Akpir K. Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements. Br J Anaesth. 2002; 89:594-8.
14. Koinig H, Wallner T, Marhofer P, Andel H, Hörauf K, Mayer N. Magnesium sulfate reduces intra- and postoperative analgesic requirements. Anesth Analg. 1998; 87:206-10
15. Pascual-Ramírez J, Gil-Trujillo S, Alcantarilla C. Intrathecal magnesium as analgesic adjuvant for spinal anaesthesia: A meta-analysis of randomized trials. Minerva Anestesiol. 2013; 79:667-7.